Amgen Inc. (AMG.DE)
| Previous close | 255.20 |
| Open | 261.05 |
| Bid | 254.90 x 20000 |
| Ask | 255.70 x 9000 |
| Day's range | 257.45 - 261.05 |
| 52-week range | 196.60 - 306.00 |
| Volume | |
| Avg. volume | 585 |
| Market cap | 139.685B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 22.08 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.29 (3.25%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Reuters
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.
- Zacks
What's in the Cards for Amgen (AMGN) This Earnings Season?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
- Zacks
Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
